Rapport Therapeutics, Inc. · NASDAQ:RAPP

Rapport Therapeutics — Investor Presentation (May 2024)

40 slides from Rapport Therapeutics's investor presentation, May 2024

  1. Slide 1: Corporate overview

    fe) rapport therapeutics Corporate overview May 2024

  2. Slide 2: Disclaimer

    Disclaimer This presentation contains forward-looking statements of Rapport Therapeutics, Inc. (“Rapport,” the “Company,” “we,” “us,” or “our”) that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including stateme

  3. Slide 3: Leadership with track record of innovation and expertise

    Leadership with track record of innovation and expertise Management Team David Bredt, M.D., Ph.D.1,2 Abe Ceesay1 Brad Galer, M.D. Founder, Chief Scientific Officer Chief Executive Officer Chief Medical Officer 20 years neuroscience drug discovery 15+ years commercial and executive 20+ years biopharm

  4. Slide 4: Ushering in a new era of precision neuroscience

    Ushering in a new era of precision neuroscience Vision: To become a leader in precision neuroscience through the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders Potential for differentiated approach to generate

  5. Slide 5: Current state and limitations of neuromedicine compel the creation of Rapport

    We believe the current state and limitations of neuromedicine compels the creation of Rapport RAPs are components of the broader neuronal receptor complexes and play critical roles in regulating receptor assembly and function Conventional CNS drug discovery The potential of RAPs Drugs interact with

  6. Slide 6: Advancing our precision neuroscience pipeline

    Advancing our precision neuroscience pipeline to potentially address large market opportunities Next Expected Category Program Discovery Preclinical Phase 1 Phase 2 Phase 3 Milestone Ph1 MAD results 2Q 2024 RAP-219 Ph2a: Focal Epilepsy* Trial initiation Mid-2024 Topline results Mid-2025 TARPγ8 RAP-2

  7. Slide 7: Focal epilepsy is a large market with high unmet need

    Focal epilepsy is a large market with high unmet need Key highlights of U.S. focal epilepsy market Limitations of current therapies U.S. Epilepsy Patients Limited Efficacy: Despite over >20 FDA approved x 3.0M (ages 18+) anti-seizure medications (ASMs), 30-40% of patients are drug-resistant1 x 60% %

  8. Slide 8: RAP-219 is a pipeline in a product opportunity

    RAP-219 is a “pipeline in a product” opportunity Expanding the potential of RAP-219 Focal epilepsy Peripheral neuropathic pain Bipolar disorder U.S. patients: 1.8 million1 U.S. patients: ~5.6 million2 U.S. patients: ~7 million3 TARPg8 is a preclinically and clinically validated target for epilepsy,

  9. Slide 9: RAP-219 overview

    RAP-219 overview A. Mechanism of action and preclinical development B. Phase 1 SAD/MAD trials C. Phase 2a proof-of-concept trial in focal epilepsy D. RAP-219 in peripheral neuropathic pain and bipolar disorder 9

  10. Slide 10: AMPAR inhibition is a clinically validated approach for epilepsy

    AMPAR inhibition is a clinically validated approach for epilepsy Hippocampus and cortex are important sites of AMPA receptors (AMPAR) in epilepsy focal onset seizure origination ISBN 978-0-07-129621-6 • AMPA type glutamate receptors at excitatory • Hippocampus is a common seizure initiation site, wi

  11. Slide 11: Molecular science of transmembrane AMPA regulatory proteins (TARPs)

    Molecular science of transmembrane AMPA regulatory proteins (TARPs) TARPs: Auxiliary subunits that associate with AMPA receptors in the brain Crucial for regulating the trafficking, subcellular localization and gating of AMPA receptors • TARPs display distinct regional expression profiles, offering

  12. Slide 12: Highly potent and selective TARPg8 AMPAR NAM

    Observed to be highly potent and selective TARPg8 AMPAR NAM RAP-219 potency and selectivity TARPg8 clinical PET in human TARPg8-containing AMPA receptors (IC50) ~100 pM vs. AMPA receptors (GluA1) lacking TARPs >100,000x vs. AMPA receptors containing other TARPs (g2, g3, g4, g7) >4,000x vs. NMDA rece

  13. Slide 13: Differentiated precision preclinical profile of RAP-219

    Differentiated precision preclinical profile of RAP-219 Corneal kindling responders and Receptor occupancy (%) in rats rotarod failures in mice EC70 % Corneal Kindling Responders % Rotarod Failures 7 ng/mL • Oral administration of RAP-219 (0.001-10 mg/kg) • Valid model in focal epilepsy • Plasma EC7

  14. Slide 14: RAP-219 precision could improve the therapeutic index

    RAP-219 precision has the potential to significantly improve the therapeutic index 160 Corneal kindling mouse model therapeutic index >150 (TD50 rotarod/ED50 efficacy) for RAP-2191 and other ASMs2 140 120 Therapeutic Index 100 80 60 >44 40 25 20 9.5 5.6 5.5 5.3 4.9 > 4.6 3.1 <2.3 1.3 0 1 am am e e e

  15. Slide 15: TARPg8 NAM effectiveness persists with repeat dosing

    TARPg8 NAM effectiveness persists with repeat dosing Antiseizure activity maintained after prolonged exposure Corneal Kindling Responders (%) • Efficacy in corneal kindling used to evaluate RTX-1738 (an analog of RAP- 219) • RTX-1738 (3 mg/kg) tested following either single day or seven consecutive

  16. Slide 16: TARPγ8 AMPAR NAMs active in preclinical epilepsy models

    TARPγ8 AMPAR NAMs active in preclinical epilepsy models Preclinical epilepsy models are highly translatable, with probabilities of clinical success up to 70%, according to epileptologist Jackie French Model • Robust efficacy across a broad array of Corneal Kindling – mouse* preclinical focal and gen

  17. Slide 17: RAP-219 overview

    RAP-219 overview A. Mechanism of action and preclinical development B. Phase 1 SAD/MAD trials C. Phase 2a proof-of-concept trial in focal epilepsy D. RAP-219 in peripheral neuropathic pain and bipolar disorder 17

  18. Slide 18: RAP-219 Phase 1 SAD/MAD trials

    RAP-219 Phase 1 SAD/MAD trials • In Phase 1, RAP-219 was generally well tolerated • No serious adverse events were reported • No clinically meaningful abnormal changes in labs, ECGs, or vital signs • In SAD trial, treatment related TEAEs were generally consistent with the effects seen in non-clinica

  19. Slide 19: RAP-219 first-in-human Phase 1 trials

    RAP-219 first-in-human Phase 1 trials Single ascending dose (SAD) trial: RAP-219-101 Multiple ascending dose (MAD) trial: RAP-219-102 Part 1 • Randomized, double-blind, placebo- controlled multiple ascending dose trial • Randomized, double-blind, placebo- controlled single ascending dose trial • 5 c

  20. Slide 20: RAP-219 SAD vs. MAD exposures

    RAP-219 SAD vs. MAD exposures MAD trial achieved 3-fold higher Cmax than SAD trial1 MAD Trial Cohort 4 - 0.75 mg/day Multiple Dose (Day 28) 20 MAD Trial Cohort 5 - 1.25 mg/day Multiple Dose (Day 28) 18 SAD Trial - 2.0 mg Single Dose 16 SAD Trial - 3.0 mg Single Dose RAP-219 Concentration (ng/mL) 14

  21. Slide 21: RAP-219 MAD blinded trial results

    RAP-219 MAD blinded trial results At highest dose, no TEAEs above Grade 1 and no treatment-related TEAEs Cohort 1 Cohort 2 Cohort 3 Cohort 4 Cohort 5 Treatment Emergent Adverse Events 0.25 mg × 2 0.25 mg × 1 0.5 mg × 4 0.75 mg × 4 0.75 mg for 5 days, (TEAEs) in Phase 1 RAP-219-102 (MAD) weeks or pla

  22. Slide 22: Potentially optimal target profile emerging for RAP-219

    Potentially optimal target profile emerging for RAP-219 in focal epilepsy Ideal Product Profile RAP-219 Emerging Profile Reduces seizures potently • At low dose, reduced seizures in validated preclinical epilepsy models without evidence of sedation Displays no dose limiting • Highest dose evaluated

  23. Slide 23: RAP-219 overview

    RAP-219 overview A. Mechanism of action and preclinical development B. Phase 1 SAD/MAD trials C. Phase 2a proof-of-concept trial in focal epilepsy D. RAP-219 in peripheral neuropathic pain and bipolar disorder 23

  24. Slide 24: Phase 2a proof-of-concept trial in focal epilepsy

    Phase 2a proof-of-concept trial in focal epilepsy Key design considerations for an ideal trial • Same population to be used in registrational trials – refractory FOS patients • Informs dose selection and effect size • Utilizes a recognized seizure biomarker • Enables rapid progression into registrat

  25. Slide 25: Focal epilepsy patients with an RNS system

    Focal epilepsy patients with a responsive neurostimulation (RNS) system • RNS system patients had similar demographics to those enrolled in a third-party registrational FOS study1 (duration of epilepsy, # of seizures, # of ASMs) • The RNS system is an FDA-approved implantable device that continually

  26. Slide 26: Long episodes biomarker predicts clinical response

    Long episodes – a biomarker-based endpoint demonstrated to predict clinical response Change in seizure activity recorded through intracranial EEG (iEEG) predicted ASM clinical response • 30-40% reduction in LEs within 1-4 weeks of new ASM was associated with a >50% seizure reduction1 “Long episode r

  27. Slide 27: RAP-219 Phase 2a PoC trial in focal epilepsy

    RAP-219 Phase 2a PoC trial in focal epilepsy Principal Investigator: Design Overview: Jacqueline French, M.D. • Signal detection trial in adult drug-resistant focal Professor, Neurology, NYU Grossman School of epilepsy patients with implanted RNS systems Medicine • Multi-center open-label trial to e

  28. Slide 28: RAP-219 Phase 2a PoC trial schema

    RAP-219 Phase 2a PoC trial schema in focal epilepsy Trial schema 4-week 8-week open-label 8-week pre-treatment period treatment period follow-up period Eligibility criteria review Including review of 8 weeks of 28-day RAP-219 washout retrospective RNS system data prospective RAP-219 treatment period

  29. Slide 29: RNS PoC comparability to Phase 2b/3 trial

    RNS PoC comparability to Phase 2b/3 trial RNS system patients similar to those enrolled in third-party Phase 2b/3 trials NeuroPace long-term-treatment retrospective study Phase 2 trial example published in 2020 (Cenobamate)* Clinical characteristic Value Clinical characteristic Study Drug Placebo Ag

  30. Slide 30: Focal epilepsy PoC model comparison

    Focal epilepsy PoC model comparison Photosensitivity Transcranial Magnetic Stimulation Ideal Model RNS (PPR) (TMS) Uses focal epilepsy Yes No No patient population Long episode reduction Generalized Recognized seizure TMS-evoked EEG shown to predict clinical photoparoxysmal EEG biomarker potentials

  31. Slide 31: RAP-219 overview

    RAP-219 overview A. Mechanism of action and preclinical development B. Phase 1 SAD/MAD trials C. Phase 2a proof-of-concept trial in focal epilepsy D. RAP-219 in peripheral neuropathic pain and bipolar disorder 31

  32. Slide 32: Chronic peripheral neuropathic pain

    Chronic peripheral neuropathic pain Strong mechanistic and compelling preclinical data for RAP-219 Peripheral neuropathic pain Rationale for RAP-219 • Diagnosed prevalence of ~5.6 million1 in the U.S. • TARPγ8 is expressed in areas of the CNS associated with pain • Conditions include painful diabeti

  33. Slide 33: Preclinical evidence supporting RAP-219 in chronic pain

    Preclinical evidence supporting RAP-219 in chronic pain Study of RTX-1738, TARPg8 NAM (RAP-219 analog) RTX-1738 attenuates tactile allodynia in spinal nerve ligation (SNL) rat model Starting on Day 16 (third day of dosing) and continuing through Day 20, paw withdrawal thresholds were RTX-1738 elevat

  34. Slide 34: Bipolar disorder acute mania

    Bipolar disorder acute mania Strong mechanistic data for RAP-219 Bipolar disorder Rationale for RAP-219 • Affects 2.8 percent of the adult population in the • Bipolar disorder is associated with hyperactivity US (approximately 7 million adults) in the hippocampus, where TARPγ8 is enriched • Extreme

  35. Slide 35: Ongoing research of RAP-219 to inform future development

    Ongoing research of RAP-219 to inform future development MAD 2 & PET studies to evaluate escalation pace and receptor occupancy RAP-219-104 (MAD Trial 2) Positron Emission Tomography (PET) Trial • Objective: Assess dosing regimens that may • Objective: Confirm human brain target enable reaching ther

  36. Slide 36: nAChR discovery programs

    nAChR discovery programs § rapport therapeutics

  37. Slide 37: a6 nAChR program

    a6 nAChR program Preclinically-validated approach to neuropathic pain Chrna6 WT Chrna4 WT • nAChR agonists have been observed to be efficacious 150 Chrna6 KO Chrna4 KO in third-party preclinical and clinical neuropathic pain 125 studies; preclinical evidence in acute, inflammatory, and neuropathic p

  38. Slide 38: a9a10 nAChR program

    a9a10 nAChR program Potential for first-in-class approach to hearing disorders • Potential for a9a10 nAChRs in hearing disorders demonstrated in preclinical studies • Engagement of a9a10 has been observed to mitigate hearing loss in preclinical models • Our RAP platform technology enabled Rapport to

  39. Slide 39: Charting new paths in neuroscience with groundbreaking precision design

    Rapport Therapeutics: Charting new paths in neuroscience with groundbreaking precision design Experienced leadership Lead asset in clinical development for Proven track record of building treatment of focal epilepsy companies, novel therapies, and Data support initiating Phase 2a proof-of- developme

  40. Slide 40: Thank you

    fe) rapport therapeutics Thank you

Rapport Therapeutics — Investor Presentation (May 2024) on 6ix